Skip to main content
. 2018 Sep 4;8:13208. doi: 10.1038/s41598-018-31417-2

Figure 4.

Figure 4

Functional evaluation of the recombinant anti-CD20 mAb in vitro. (a,b) CD20-binding activity of the recombinant mAb. Daudi (a) and Raji (b) cells were incubated with serial log dilutions of the mAbs, and their binding activities were assayed by flow cytometry using a FITC-conjugated goat anti-human IgG (H + L). Data are presented as the mean ± SD (n = 3). (c,d) CDC induced by the anti-CD20 mAb. Daudi (c) and Raji (d) cells were incubated with increasing concentrations of mAbs in the presence of human serum. CDC activity was measured using a Luminescent Cell Viability Assay Kit. Data are presented as the mean ± SD (n = 3). (e) ADCC induced by the anti-CD20 mAb. ADCC activity against Raji cells was determined using human PBMCs as effector cells at an effector-to-target cell ratio of 5:1. The activity was measured using a standard LDH assay. Data are presented as the mean ± SD (n = 3).